Assessing risk factors: Prevention of inhibitors in haemophilia

Haemophilia

Volumn 16, Issue SUPPL. 2, 2010, Pages 10-15

  Chambost, H ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Epidemiology; Haemophilia; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

AFRICAN AMERICAN; AGE DISTRIBUTION; CONTINUOUS INFUSION; DNA POLYMORPHISM; DRUG EXPOSURE; ENVIRONMENTAL FACTOR; ETHNICITY; FAMILY HISTORY; GENETIC RISK; GENOTYPE; HEMOPHILIA; HEMOPHILIA A; HUMAN; MISSENSE MUTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION;

AGE FACTORS; BLOOD COAGULATION FACTOR INHIBITORS; CYTOKINES; FACTOR IX; FACTOR VIII; GENOTYPE; HEMOPHILIA A; HUMANS; INFANT; INFANT, NEWBORN; RISK FACTORS;

EID: 76749138587     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02197.x     Document Type: Review

References (36)

1. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: pathophysiology. Haemophilia 2004, 10(Suppl 4):146-51.
2. Haya S, Moret A, Cid AR. Inhibitors in haemophilia A: current management and open issues. Haemophilia 2007, 13(Suppl 5):52-60.
3. Jiménez-Yuste V, Alvarez MT, Martín-Salces M. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009, 15:203-9.
4. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003, 102:2358-63.
5. Berntorp E, Shapiro A, Astermark J. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006, 12(Suppl 6):1-7.
6. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006, 12(Suppl 3):52-60.
7. Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009, 113:11-7.
8. DiMichele DM. Treatment of haemophilia. April 2008;7. Inhibitors in Haemophilia: A Primer http://www.wfh.org, World Federation of Haemophilia 2008, Available at: Last accessed 30/09/2009
9. DiMichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004, 10(Suppl 4):140-5.
10. Kasper CK, Aledort L, Aronson D. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975, 34:612.
11. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999, 82:500-4.
12. Astermark J, Berntorp E, White GC, Kroner BL. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001, 7:267-72.
13. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999, 5:145-54.
14. Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004, 1(Suppl 1):82-8.
15. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003, 29:23-30.
16. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 geneassociated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-72.
17. Astermark J, Oldenburg J, Carlson J. Polymorphisms in the TNFA gene as are nd the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-45.
18. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007, 5:263-5.
19. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2009, 1-5. [Epub ahead of print]
20. Wieland I, Wermes C, Eifrig B. Inhibitor-Immunology-Study. Different HLA-types seem to be involved in the inhibitor development in haemophilia A. Hamostaseologie 2008, 28(Suppl 1):S26-8.
21. Viel KR, Ameri A, Abshire TC. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009, 360:1618-27.
22. Gouw SC, ter Avest PC, van Helden PM, Voorberg J, van den Berg HM. Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment. Haemophilia 2009, 15:712-7.
23. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-54.
24. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007, 109:4693-7.
25. Chalmers EA, Brown SA, Keeling D. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007, 13:149-55.
26. Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001, 113:600-3.
27. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003, 89:475-9.
28. Santagostino E, Mancuso ME, Rocino A. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005, 130:422-7.
29. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007, 5:1383-90.
30. Sharathkumar A, Lillicrap D, Blanchette VS. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003, 1:1228-36.
31. Goudemand J, Rothschild C, Demiguel V. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006, 107:46-51.
32. Rivard GE, Lillicrap D, Poon MC. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age? Haemophilia 2005, 11:335-9.
33. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007, 13(Suppl 5):65-8.
34. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006, 12:124-7.
35. Chambost H, Meunier S. Relevance of early paediatric care for boys with severe haemophilia. Arch Pediatr 2006, 13:1423-30.
36. Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol 2006, 13:316-22.